Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year High – What’s Next?

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reached a new 52-week high during mid-day trading on Thursday. The company traded as high as $82.98 and last traded at $80.8850, with a volume of 226,231 shares. The stock had previously closed at $78.84.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Citigroup lifted their price target on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Canaccord Genuity Group upped their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Finally, Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of “Moderate Buy” and an average target price of $93.14.

Kiniksa Pharmaceuticals International Price Performance

The stock’s 50-day moving average price is $77.87 and its 200 day moving average price is $63.95. The firm has a market cap of $6.13 billion, a P/E ratio of 81.02 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. As a group, analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CAO Michael Megna sold 4,600 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total value of $369,380.00. Following the completion of the transaction, the chief accounting officer owned 29,062 shares in the company, valued at $2,333,678.60. This trade represents a 13.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the transaction, the director owned 11,672 shares of the company’s stock, valued at $950,450.96. The trade was a 23.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 51.98% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KNSA. Allworth Financial LP increased its position in shares of Kiniksa Pharmaceuticals International by 42.0% during the 2nd quarter. Allworth Financial LP now owns 453 shares of the company’s stock worth $29,000 after purchasing an additional 134 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Kiniksa Pharmaceuticals International by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock worth $648,000 after purchasing an additional 209 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 21.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock valued at $95,000 after buying an additional 223 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Kiniksa Pharmaceuticals International by 3.1% in the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after buying an additional 293 shares during the last quarter. Finally, Nykredit A S acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at approximately $34,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for patients with debilitating diseases, including conditions driven by immune-system and inflammatory responses. The company’s strategy centers on targeted medicines intended to address significant unmet medical needs in specialty markets.

Kiniksa’s primary commercial product is ARCALYST (rilonacept), an interleukin-1 blocker. In the United States, ARCALYST is approved for the treatment of recurrent pericarditis and for reducing the risk of recurrence in adults and children age 12 and older.